Antidepressants and pregnancy: What parents-to-be should know about ADHD, autism risks
Antidepressants and pregnancy: What parents-to-be should know about ADHD, autism risks
Antidepressants and pregnancy – Recent years have seen increasing scrutiny over the potential effects of antidepressants on fetal development, particularly concerning conditions like autism and attention deficit hyperactivity disorder (ADHD). A new study published in The Lancet Psychiatry offers the most comprehensive analysis to date, examining the relationship between antidepressant use by both parents before and during pregnancy and the likelihood of neurodevelopmental disorders in their offspring. The research, which pooled data from 37 prior studies, involved over 600,000 pregnant women who used antidepressants and nearly 25 million pregnancies without medication exposure, providing a robust foundation for its conclusions.
Key Findings of the Study
The study revealed that while initial associations between antidepressant exposure and ADHD or autism appeared significant, these links diminished substantially when researchers accounted for other influencing factors. For instance, maternal use of antidepressants during pregnancy was initially linked to a 35% increased risk of ADHD and a 69% heightened chance of autism without intellectual disabilities. However, after adjusting for genetic predispositions, family history, and reasons for medication use, these risks dropped significantly. The adjusted autism risk, for example, was reduced to about 15%, suggesting that many of the observed correlations were not directly caused by the drugs themselves.
Paternal antidepressant use also showed some association, with a 46% higher risk of ADHD and a 28% increased likelihood of autism. Yet, similar to maternal use, these figures weakened when researchers controlled for confounders. Dr. Wing Chung Chang, a co-senior author of the study and clinical professor of psychiatry at the University of Hong Kong, emphasized that the findings point to a larger picture: “The higher rates of ADHD and autism seen in previously exposed groups are largely driven by the underlying vulnerability of these mothers and families.” This insight challenges earlier assumptions that antidepressants are the primary cause of such developmental conditions.
“Antidepressants are the mainstay medication treatment for depressive disorder, which affects more than 10% of pregnant women worldwide,” Chang noted. The study’s findings reinforce the importance of these medications in managing maternal mental health, especially when untreated depression poses its own risks to both mother and child.
Context of the Research
Researchers aimed to address gaps in previous studies, which often lacked sufficient data on confounders and varied in methodology. Until now, no comprehensive review had evaluated the impact of antidepressant class, specific drug types, dosage levels, and the combined effects of maternal and paternal use during the preconception and prenatal periods. These limitations contributed to conflicting evidence and heightened public concern, particularly following FDA discussions in July 2025 that raised warnings about SSRIs—a class of antidepressants widely prescribed during pregnancy.
RFK Jr., a prominent figure in the debate over psychiatric medications, has advocated for a reevaluation of antidepressant use in pregnancy. His initiative highlights the need to balance potential risks with the benefits of treating maternal depression, a perspective the new study supports. “This concern has been amplified by the July 2025 FDA expert panel discussions,” Chang explained, adding that the panel’s focus on strengthening warnings for SSRIs has drawn attention to possible risks such as autism, miscarriage, and birth defects. However, the study’s authors argue that these warnings may overlook the critical role of untreated perinatal mood disorders in harming both mother and child.
Reassessing Past Studies and Their Limitations
Earlier research on antidepressant use during pregnancy often relied on smaller sample sizes and incomplete assessments of confounders. As a result, findings varied widely, creating confusion among parents and healthcare providers. The new meta-analysis, however, leverages a larger dataset, offering more reliable insights. Dr. Jonathan Alpert, a psychiatrist at Montefiore Medical Center in New York City, acknowledged the natural concern parents and clinicians have about psychiatric medications’ impact on children. “Pregnancy is inevitably a time of heightened worry about one’s health and the health of one’s unborn child,” he stated, emphasizing the need for informed decision-making.
The study also underscores the importance of individualized treatment plans. While some antidepressants may carry slight risks, the overall evidence suggests that these risks are relatively small compared to the consequences of leaving maternal depression unaddressed. “Our findings do not provide strong evidence that prenatal antidepressant exposure causes neurodevelopmental disorders,” Chang reiterated. Instead, the research highlights the necessity of weighing medication benefits against the risks of untreated mental health conditions, particularly in the context of a pregnant woman’s well-being.
Implications for Parents and Clinicians
For parents planning to conceive or those already in pregnancy, the study’s results affirm current clinical guidelines. These guidelines generally recommend continuing antidepressant treatment during pregnancy if needed, as the potential risks of untreated depression can be significant. The study’s authors hope their findings will help alleviate unnecessary anxiety while guiding more nuanced discussions between patients and healthcare providers. “We wanted to help clinicians and patients make informed choices,” Chang said, stressing the importance of considering both the medication’s impact and the mother’s mental health needs.
Experts agree that the study adds clarity to a complex issue. “The potential impact of psychiatric medications on children is naturally a source of concern for parents and prescribing clinicians alike,” Alpert remarked. Yet, he also pointed out that the risk of untreated depression during pregnancy—such as preterm birth, low birth weight, and postpartum complications—cannot be ignored. The study’s comprehensive approach, which includes both maternal and paternal medication use, addresses a critical gap in previous research and provides a more holistic view of the factors influencing neurodevelopmental outcomes.
With the growing prevalence of perinatal mental health disorders, the findings of this study carry broader implications. They suggest that while antidepressants may play a role in certain cases, their use during pregnancy is not inherently harmful. Instead, the decision to continue or discontinue medication should be based on a thorough evaluation of each individual’s circumstances. As Chang highlighted, the study serves as a reminder that “the significant positives of antidepressants and the risks of untreated depression” must be considered together. This balanced perspective is essential for guiding parents through the challenges of pregnancy and ensuring they have the information needed to make thoughtful, informed decisions.
